2025.07.26本文字数:461,阅读时长大约1.16分钟导读:7月25日,维立志博港交所首秀飙涨一倍,市值冲140亿港元;PD-L1/4-1BB双抗LBL-024手握“突破疗法”,肺外神经内分泌瘤有望率先撞线,三抗ADC借NewCo出海。2025年7月25日,维立志博正式登陆港交所主板,挂牌首日高开107%,总市值一举冲破140亿港元大关。维立志博创立于2012年,其首发产品LBL-024...
Source Link2025.07.26本文字数:461,阅读时长大约1.16分钟导读:7月25日,维立志博港交所首秀飙涨一倍,市值冲140亿港元;PD-L1/4-1BB双抗LBL-024手握“突破疗法”,肺外神经内分泌瘤有望率先撞线,三抗ADC借NewCo出海。2025年7月25日,维立志博正式登陆港交所主板,挂牌首日高开107%,总市值一举冲破140亿港元大关。维立志博创立于2012年,其首发产品LBL-024...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.